LENSAR CEO Nick Curtis will speak at BTIG Ophthalmology Day, with 1-on-1 investor meetings.
Quiver AI Summary
LENSAR, Inc., a medical technology company specializing in robotic laser solutions for cataract treatment, announced that CEO Nick Curtis will participate in a fireside chat at the BTIG 4th Annual Ophthalmology Day on December 2, 2024. The event will also include one-on-one meetings with institutional investors. LENSAR's primary product is the ALLY Robotic Cataract Laser System™, which features a dual-modality laser and AI integration to enhance surgical precision and efficiency in both operating and in-office settings. The system is designed to improve outcomes for cataract surgeries, particularly in managing astigmatism, and incorporates LENSAR's proprietary Streamline® software to assist surgeons.
Potential Positives
- Participation in a high-profile event like the BTIG 4th Annual Ophthalmology Day enhances LENSAR's visibility and credibility in the ophthalmology sector.
- Hosting 1-on-1 meetings with institutional investors could lead to increased investment interest and potential funding opportunities for LENSAR's innovative products.
- The announcement highlights LENSAR's focus on advanced technology, specifically the ALLY Robotic Cataract Laser System™, emphasizing its cutting-edge features and operational efficiencies, which may attract attention from healthcare professionals and potential customers.
Potential Negatives
- The announcement primarily focuses on a participation in a fireside chat and meetings with investors, which may indicate limited immediate business developments or advancements.
- The exclusivity of the event to BTIG clients could suggest a lack of broader investor engagement or interest in the company's activities.
- There is no mention of recent financial performance or product developments, which may raise concerns about transparency and investor communication.
FAQ
What is the focus of LENSAR, Inc.?
LENSAR, Inc. is focused on advanced robotic laser solutions for the treatment of cataracts and managing astigmatism.
When is Nick Curtis participating in the BTIG event?
Nick Curtis will participate in the BTIG 4th Annual Ophthalmology Day on December 2, 2024, at 2 p.m. ET.
How can I listen to the BTIG fireside chat?
To listen to the live event, please contact your BTIG representative for access details.
What technology does the ALLY Robotic Cataract Laser System use?
The ALLY system incorporates a dual-modality laser and AI-driven proprietary imaging and software technologies.
What is the purpose of LENSAR's Streamline® software?
The Streamline® software is designed to guide surgeons in achieving better outcomes during cataract surgery.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LNSR Insider Trading Activity
$LNSR insiders have traded $LNSR stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LNSR stock by insiders over the last 6 months:
- GARY M WINER has traded it 10 times. They made 10 purchases, buying 5,495 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LNSR Hedge Fund Activity
We have seen 9 institutional investors add shares of $LNSR stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BRANDES INVESTMENT PARTNERS, LP added 70,200 shares (+18.8%) to their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 20,167 shares (-83.6%) from their portfolio in Q3 2024
- RENAISSANCE TECHNOLOGIES LLC removed 19,100 shares (-5.8%) from their portfolio in Q3 2024
- TWO SIGMA SECURITIES, LLC removed 17,908 shares (-100.0%) from their portfolio in Q2 2024
- PARK WEST ASSET MANAGEMENT LLC added 16,533 shares (+1.7%) to their portfolio in Q3 2024
- ENVESTNET ASSET MANAGEMENT INC added 10,460 shares (+inf%) to their portfolio in Q3 2024
- DIMENSIONAL FUND ADVISORS LP removed 8,453 shares (-1.3%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will participate in a fireside chat at the BTIG 4th Annual Ophthalmology Day on Monday, December 2, 2024 at 2 p.m. ET. Additionally, LENSAR management will host 1-on-1 meetings with institutional investors.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline ® software technology, which is designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth / Cameron Radinovic | |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR | |
| [email protected] | [email protected] / [email protected] |
